Integrated Annual Report

The report highlights a year of growth, with 2024 revenue up 17% and access coverage for UCB medicines reaching 82%. Renewable sources accounted for 86.4% of total energy consumption. UCB's net-zero target, covering absolute Scope 1, 2 and 3 emissions and aiming to reduce them by 90% by 2045, was formally validated by the SBTi.